Bioretec Achieves FDA Breakthrough Designation for RemeOs DrillPin
Bioretec Ltd, a leading innovator in biodegradable orthopedic implants, has recently been granted the prestigious Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its cutting-edge RemeOs™ DrillPin. This designation highlights the promising potential of Bioretec’s magnesium alloy technology in bone fixation, underscoring the company’s commitment to revolutionizing orthopedic care.
Overview of the RemeOs™ DrillPin
The RemeOs™ DrillPin is designed to effectively fixate bone fragments in both pediatric and adult patients, specifically addressing the needs of those with epi-metaphyseal fractures and open growth plates. It is especially critical for pediatric patients aged two years and above, where specialized fixation across growth plates is essential for effective treatment outcomes.
Significance of Breakthrough Device Designation
Receiving Breakthrough Device Designation is a significant milestone for Bioretec. This status is reserved for medical devices that demonstrate the potential to address serious medical conditions and offer considerable advantages over existing treatments. With this designation, Bioretec gains the benefit of prioritized communication and collaboration with the FDA throughout the remainder of the development and review process. This support is expected to streamline the clinical and regulatory pathways leading to the timely introduction of the DrillPin to the market.
A Milestone in Bioretec’s Journey
The RemeOs™ DrillPin is the third device in Bioretec’s RemeOs™ range to achieve Breakthrough Device Designation, following the Trauma Screw in 2021 and the Spinal Cage in 2024. According to Sarah van Hellenberg Hubar-Fisher, CEO of Bioretec, this accomplishment not only reinforces the company's innovative capabilities but also highlights the unmet clinical needs that the company is addressing. The positive recognition of the magnesium-based platform as an osteopromotive technology indicates a significant shift in fracture treatment paradigms.
Future Prospects for Bioretec
As Bioretec continues to innovate, the company plans to release a comprehensive commercialization strategy along with updates to its product development pipeline and revised financial outlook by the end of the current year. This strategic shift promises to bolster its position in the competitive U.S. orthopedic market.
Commitment to Regulatory Standards
Despite the achievements linked to the Breakthrough Device Designation, Bioretec emphasizes that this recognition does not simplify the evidence requirements for clinical data, nor does it guarantee FDA marketing authorizations or other regulatory approvals. The company remains steadfast in its dedication to meeting the rigorous standards set forth by regulatory bodies to ensure the safety and effectiveness of its innovations.
About Bioretec
Founded in Finland, Bioretec is at the forefront of advancing orthopedic solutions through fully biodegradable implant technologies. The company has established itself as a pioneer in enhancing outcomes for patients undergoing orthopedic surgeries. Bioretec’s products, available in approximately 40 countries, reflect a global commitment to innovation in medical devices, with a focus on improving patient recovery through incorporating materials that promote bone growth and healing.
Innovative Product Line
The RemeOs™ product line harnesses a high-performance magnesium alloy and hybrid composite to create absorbable materials that lead to better surgical results. These implants not only support fracture healing but are also naturally absorbed by the body, thereby eliminating the need for further surgery to remove them. Bioretec’s first RemeOs™ product was authorized in the U.S. in March 2023, and the CE mark was secured in Europe in January 2025, paving the way for broader adoption of this revolutionary technology.
Frequently Asked Questions
What is the RemeOs DrillPin?
The RemeOs DrillPin is a biodegradable orthopedic implant designed to fix bone fragments, particularly in pediatric and adult patients.
What does Breakthrough Device Designation mean?
This designation indicates that a medical device may offer significant benefits over existing options for treating serious conditions, providing expedited development support from the FDA.
Who is the CEO of Bioretec?
Sarah van Hellenberg Hubar-Fisher is the CEO of Bioretec.
Where are Bioretec's products available?
Bioretec's products are used in approximately 40 countries worldwide.
What is unique about Bioretec's technology?
Bioretec specializes in biodegradable implant technologies, which enhance bone growth and healing, thus eliminating the need for removal surgeries.
